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increasing per pack taxes by at least 10%, but smokers’ lives were slightly extended 
by the ban condition. Incremental cost effectiveness ratios for taxes and bans, relative 
to no intervention were: $29,827 and $29,814 per life year gained, respectively.
CONCLUSIONS: Both public policy strategies of taxes and bans have a minimal 
impact on life years gained over the lifetimes of smokers. Taxes showed an advantage 
in lower hospitalization and value of lives saved. In addition, taxes are revenue enhanc-
ing, while bans require additional enforcement resources. Using tobacco taxes to 
reduce tobacco consumption and subsequent tobacco-related disease is superior to
smoking bans, though the combination of the two policies may be mutually reinforcing
for behavioral change and additive in effect.
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OBJECTIVES: Clopidogrel is a frequently used drug to prevent subsequent
atherothrombotic events in patients with stroke, myocardial infarction, or peripheral
arterial diseases. Doctors should subjectively determine whether the price of clopido-
grel is justiﬁ ed by its improved therapeutic effect compared to that of aspirin, consider-
ing country-wise economic situation. This study analyzed the cost-effectiveness
of clopidogrel for atherothrombosis treatment in South Korea. METHODS: Cost-
effectiveness was analyzed using the Cambridge model; a Markov model developed
using data from the Clopidogrel versus Aspirin in Patients at Risk of Ischemic 
Events (CAPRIE) study, as per Korean situation. The effect was estimated using
data from the Framingham and Saskatchewan databases to calculate the expected
survival (in years) for various health states. Direct medical costs from the social 
perspective, direct non-medical costs, and indirect medical costs were analyzed;
applying 5% discount rate to both cost and effect. RESULTS: The 2-year follow-up 
results showed that the number of cardiovascular (CV) events and CV deaths per
1000 patients was decreased by 13.19 and 2.21, respectively, in the clopidogrel
group as compared to the aspirin group. As clopidogrel treatment decreased the inci-
dence of CV deaths; the number of life-years gained per 1000 patients was 65.65
(Framingham) and 48.20 (Saskatchewan). The incremental cost-effectiveness ratio 
determined using incremental costs per life-year gained was US$ 19,017 (Framingham) 
and US$ 25,904 (Saskatchewan). CONCLUSIONS: Our results showed that clopido-
grel was cost-effective treatment of atherothrombosis in South Korea, and evaluated 
a basis for the economic feasibility of clopidogrel administration for atherothrombosis 
treatment.
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OBJECTIVES: Syncope is a signiﬁ cant burden on the health care system and individu-
als. Screening manoeuvres including medical examination, ambulatory external moni-
toring, imaging and clinical diagnostic tests provide a presumptive diagnosis in a 
limited number of patients since syncope recurrence is unpredictable. Establishing or 
ruling out a cardiac arrhythmia as the cause is challenging, time consuming and relies 
on recording the cardiac rhythm at the time of spontaneous recurrences. The Insertable
Cardiac Monitor(ICM) is a new, efﬁ cient and accurate technique for long-term
monitoring and recording the “events” in a patient. This study assesses the cost-
effectiveness of adding the ICM to the standard diagnostic protocol in Canadian
health care system. METHODS: A decision analytic model was developed assessing 
the cost-effectiveness of the standard diagnosis approach compared to ICM from 
a Canadian provider perspective. The main clinical outcome used in the model
was “yield” deﬁ ned as the rate of correct diagnoses derived from published literature.
The frequency of resources used and associated costs were derived from literature
and the Ontario Health Insurance Policy. RESULTS: The diagnosis yield for ICM
and standard approach was 33.7% and 4.1% respectively. The model assessed
the cost per diagnosis in the two arms. The incremental cost per diagnosis was $6237 
in favour of ICM. Sensitivity analysis showed that in the lower conﬁ dence interval 
(CI) the ICM is the “dominant” option and in upper CI limits the ICER was $35,358
and below the $50,000 acceptability threshold. CONCLUSIONS: ICM is a safe,
accurate and effective device for diagnosis of syncope and should be considered as
an alternative in diagnosis of syncope. The cost of ICM is partially offset by savings 
in hospitalization. A societal perspective will reduce the ICER in favour of ICM by 
preventing complications of syncope (i.e., falls, fractures, mortality) and increase
patient HRQoL.
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OBJECTIVES: To determine the cost-effectiveness, from the Brazilian Ministry of 
Health perspective, of Fluvastatin IR 20 mg, Fluvastatin IR 40 mg, Fluvastatin IR
80 mg and Fluvastatin XL 80. Also we calculated the budget impact of introducing
Fluvastatin XL 80 mg into the current Brazilian national drug formulary. METHODS:
The cost effectiveness was determined using clinical data from published systematic
review and cost the costs were valued using government prices. The costs was in Brazil-
ian reais (BRL) and the price year was 2008 (1$US  1.63 BRL). The beneﬁ t measure
used in this economic evaluation was LDL- reduction. Using the Healtchare System
database’ data we described the evolution of consumption of statins in Brazilian
Health System. Univariate sensitivity analysis tested model robustness. We calculated 
the budget impact analysis for three years. RESULTS: The Fluvastatin XL 80 mg is
the statin more cost-effective and permits the cost reduction in BRL $26,10 per patient.
The sensitivity analysis of budget impact show that introduction Fluvastatin into for-
mulary could generate average savings of 18% of the Fluvastatin’s total budget or 
BRL 56,500 ($US 34,600). CONCLUSIONS: The inclusion of Fluvastatin XL 80 mg 
is aligned with the health authority strategy of cost containment or reduction for this 
class of medicines. Results are sensitive to the list price of drugs.
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OBJECTIVES: Existing triage strategy is suboptimal in risk stratifying Asian 
patients with chest pain. Hence, we aim to determine the cost-effectiveness of an add-
on stress myocardial perfusion imaging (MPI) in improving risk stratiﬁ cation in a 
single-centre randomized controlled trial involving Asian patients with chest pain and 
non-diagnostic ECG presenting to an emergency department (ED) in Singapore. 
METHODS: Consenting patients were randomly assigned to with or without MPI 
add-on. Patients who developed ST segment changes, elevated CKMB/ Troponin 
during the 6-hr observation were admitted without receiving the assigned interven-
tions. One-year cost-effectiveness of the two strategies (MPI vs. no MPI) was analysed
from the institution’s perspective. Inpatient costs were obtained from electronic data-
base. Outpatient costs were estimated with expert input. Effectiveness was measured
as percent patients accurately risk stratiﬁ ed at one year (i.e. high/medium risk patients 
experiencing a cardiac event and low risk patients not experiencing any cardiac event
within one year). The incremental cost-effectiveness ratio (ICER) and conﬁ dence
intervals (CI) were constructed by bootstrap analysis (percentile approach). Sensitivity 
analysis was conducted for outpatient costs. RESULTS: Cost data were available from
1418 patients (83.9% of randomized patients). The ICER of MPI vs. no MPI was
$6,334 ($13,474 to $40). 97.6% of bootstrapped replicates fell below the $0 per
accurate risk stratiﬁ cation level, indicating that the scan strategy dominated the no 
scan strategy. All bootstrap replicates fell in the north- and south-east quadrants on
the cost-effectiveness plane, conﬁ rming that the negative ICER was due only to nega-
tive cost differences. Coefﬁ cient of variation (CV) of the effect difference is 0.19. Small 
bias to standard error ratio (0.013) justiﬁ es not making bias correction in estimating 
CI. Results were insensitive to outpatient costs. CONCLUSIONS: Add-on MPI is 
cost-effective in risk stratifying patients with chest pain. Given the small CV, bootstrap
estimates are likely to be robust.
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OBJECTIVES: To demonstrate how expert elicitation can be combined with Bayesian 
decision theory to inform the decision to conduct further research and identify efﬁ cient
research design when there is limited evidence available. METHODS: Using a model 
of enhanced external counterpulsation (EECP) for the treatment of angina, expert 
elicitation was used to provide informed priors on the key model parameters where 
no evidence was available. These priors were updated with sample information to 
quantify the expected value of sample information (EVSI). The EVSI was compared 
to the costs of sampling and the expected net beneﬁ t of sample information was
obtained (ENBS). The ENBS is a measure of the societal payoff to research and pro-
vides a sufﬁ cient condition for deciding to conduct more research. Given the need to
establish if EECP has a role for treating angina and the paucity of effectiveness 
evidence available, the ENBS was used to determine the type of study required, 
the optimal sample size, the appropriate length of follow-up and the endpoints 
that should be included. RESULTS: There is signiﬁ cant value to future research 
in EECP. This research is most valuable when directed towards establishing the
